latest news releases from the newsroom
MorphoSys to Receive Milestone Payment for Guselkumab Phase 3 Program
MARTINSRIED/MUNICH, Germany, Oct. 22, 2014 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that its collaborator Janssen Biotech, Inc. has initiated a phase 3 clinical trial in moderate to severe plaque-type psoriasis with the HuCAL antibody guselkumab (CNTO1959). The event triggered a clinical milestone payment to MorphoSys. Further financial details were not disclosed.
Ad hoc: MorphoSys Updates its 2014 Financial Guidance
MARTINSRIED/MUNICH, Germany, Oct. 22, 2014 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX OTC: MPSYY) today announced that it is adjusting its EBIT guidance for the current year. MorphoSys now expects a negative EBIT in the range of EUR -5 million to EUR -8 million (from previously EUR -11 million to EUR -16 million). Reasons for the change are the now confirmed receipt of a milestone payment from Janssen, which directly affects the profit line, as well as a partial shift of proprietary development expenses to 2015. Revenues are now expected at the upper end of the previously communicated guidance range of EUR 58 million to EUR 63 million.
QCR Holdings, Inc.
QCR Holdings, Inc. Announces Net Income of $4.1 Million for the Third Quarter of 2014
MOLINE, Ill., Oct. 22, 2014 (GLOBE NEWSWIRE) -- QCR Holdings, Inc. (Nasdaq:QCRH) today announced net income of $4.1 million for the quarter ended September 30, 2014, or diluted earnings per common share ("EPS") of $0.50, with no preferred stock dividends due to the redemption of all outstanding shares of Series F Preferred Stock in the second quarter of 2014. By comparison, for the quarter ended June 30, 2014, the Company reported net income of $4.0 million, or diluted EPS of $0.45 after preferred stock dividends of $374 thousand. For the third quarter of 2013, the Company reported net income of $3.8 million, or diluted EPS of $0.51 after preferred stock dividends of $811 thousand. On December 23, 2013, the Company converted all $25.0 million of its outstanding shares of Series E Preferred Stock to common stock, which resulted in the issuance of 2,057,502 shares of common stock. The conversion strengthened tangible common equity ("TCE") and reduced the Company's annual preferred stock dividend commitment by $1.75 million, which will help to further strengthen future TCE and increase earnings per share.